Leukemia is a hematological malignancy that originates from hematopoietic stem cells in the
bone marrow. Significant progress has made in understanding its pathogensis and in …

Introduction Patients with chronic myeloid leukemia in chronic phase (CP-CML) who are
resistant or intolerant to second-generation tyrosine kinase inhibitors (TKIs) may benefit from …

Introduction The therapeutic strategy and management of chronic myeloid leukemia (CML)
have rapidly improved with the discovery of effective tyrosine kinase inhibitors (TKIs) to …

Myeloid neoplasms arise from malignant primitive cells, which exhibit growth advantage
within the bone marrow microenvironment (BMM). The interaction between these malignant …

Ganoderma lucidum methanolic extract (GLME) has attracted tremendous attention due to
its exceptional antimicrobial and anticancer properties that can be delicately tuned by …

Thimet oligopeptidase (THOP) is a cytosolic metallopeptidase known to regulate the fate of
post-proteasomal peptides, protein turnover and peptide selection in the antigen …

Myeloproliferative neoplasms (MPN) are chronic clonal disorders characterized by
overproduction of myeloid-lineage blood cells and potential risk of evolution to acute …

OBJECTIVE: Cardiovascular system health becomes important with the extended survival of
chronic myeloid leukemia (CML) patients. Cardiotoxicities are related to the second-and …

Purpose The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML)
is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML …

Bcr-Abl is a key driver in the pathophysiology of CML. Broadening the chemical diversity of
Bcr-Abl kinase inhibitors to overcome drug resistance is a current medical demand for CML …